Cosp.Wa

COSP.WA's capital structure is characterized by a debt-to-equity ratio of 0.31, indicating a relatively conservative leverage position. However, the company's liquidity is rated as medium, with a current ratio of 1.0, suggesting that it has just enough current assets to cover its current liabilities. The company's free cash flow is negative at -5,037,500, which may limit its ability to fund operations or invest in growth without external financing.

Profitability metrics for COSP.WA are weak, with a return on equity of -43.81% and a return on assets of -20.73%. These figures are below the industry median for pharmaceutical companies, which typically exhibit positive returns due to high-margin product offerings. The company's operating income is negative at -4,086,840, and its net income is also negative at -4,883,590, indicating that it is currently unprofitable.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases the company's exposure to market-specific risks, such as regulatory changes or economic downturns in its primary operating region. The absence of segment or geographic breakdown in the financial data limits the ability to assess the company's risk profile in detail.

COSP.WA's growth trajectory is uncertain, with no disclosed revenue growth in the most recent fiscal year. The company's operating cash flow is negative at -1,028,430, and its capital expenditures are also negative at -1,395,410, suggesting that it is not investing in new projects or expanding its operations. The lack of growth in revenue and the negative cash flow raise concerns about the company's long-term sustainability.

The company's risk profile is elevated due to its negative net cash position after subtracting total debt. This indicates that the company may face liquidity challenges in the near term. The risk of dilution is currently low, but the company's negative free cash flow and operating cash flow suggest that it may need to raise additional capital in the future, which could lead to share dilution. The company has not disclosed any recent equity offerings or dilutive events, but the need for capital could increase the risk of dilution in the future.

There are no recent events or filings disclosed in the available data that would indicate significant changes in the company's operations or financial position. The company has not issued any press releases or filed any 10-K or 10-Q reports that would provide additional insight into its business strategy or financial performance. The absence of recent disclosures limits the ability to assess the company's current direction and strategic priorities.